Diabetic nephropathy is the most common cause of end-stage renal disease, affecting about one-third of subjects with diabetes mellitus 1 . Early diabetic nephropathy is characterized by mesangial hypertrophy and glomerular hyperfiltration with microalbuminuria. Sirtuin 1 (Sir2, also called Sirt1) is a NAD + -dependent protein deacetylase and a member of the sirtuin class of proteins. Sirt1, a mammalian ortholog of Sir2, deacetylates histones and various transcription factors, protecting against acute and chronic stress 2,3 . Sirt1 mitigates diabetes by attenuating hepatic insulin resistance 4,5 and enhancing pancreatic insulin secretion 6 . Recently, the renal protective effects of Sirt1 (refs. 7, 8 ) and a pathogenic role for Sirt1 in diabetic nephropathy 9-12 have been reported, although the relationship between renal Sirt1 and the pathogenesis of kidney damage in diabetes has not been investigated.
Diabetic nephropathy is the most common cause of end-stage renal disease, affecting about one-third of subjects with diabetes mellitus 1 . Early diabetic nephropathy is characterized by mesangial hypertrophy and glomerular hyperfiltration with microalbuminuria. Sirtuin 1 (Sir2, also called Sirt1) is a NAD + -dependent protein deacetylase and a member of the sirtuin class of proteins. Sirt1, a mammalian ortholog of Sir2, deacetylates histones and various transcription factors, protecting against acute and chronic stress 2, 3 . Sirt1 mitigates diabetes by attenuating hepatic insulin resistance 4, 5 and enhancing pancreatic insulin secretion 6 . Recently, the renal protective effects of Sirt1 (refs. 7,8) and a pathogenic role for Sirt1 in diabetic nephropathy [9] [10] [11] [12] have been reported, although the relationship between renal Sirt1 and the pathogenesis of kidney damage in diabetes has not been investigated.
Our group recently produced transgenic (TG) mice overexpressing SIRT1 specifically in the PTs and reported that SIRT1 alleviated acute kidney injury 13, 14 . In diabetic nephropathy, PT changes are evident even in the early stages 15 . PT changes are reportedly closely linked to loss of renal function and predict the progression of diabetic nephropathy more accurately than glomerular changes 15 . Therefore, our TG mice are good models for exploring the PT-specific role of Sirt1 in diabetic nephropathy. We used these mice, as well as PT-specific Sirt1 knockout (KO) mice, to investigate the protective role of Sirt1 in diabetes-induced albuminuria.
RESULTS

Sirt1 in diabetes and the effects of SIRT1 overexpression
Downregulation of Sirt1 expression in a diabetic milieu or highglucose condition has been reported in various cells 16, 17 . We examined Sirt1 expression in PTs and glomeruli after streptozotocin (STZ) treatment of male C57BL/6J mice. By immunostaining, we detected Sirt1 expression in both PTs and glomeruli before STZ treatment. Eight weeks after STZ treatment, Sirt1 levels were decreased in PTs but remained unchanged in glomeruli. Twenty-four weeks after STZ treatment, Sirt1 levels in glomeruli were also decreased (Fig. 1a) . Laser microdissection followed by RT-PCR revealed that Sirt1 mRNA expression decreased in PTs before it decreased in glomeruli in diabetic mice ( Fig. 1b and Supplementary Fig. 1a,b) . These observations indicate that the molecular alterations in PTs occur at a very early stage in diabetes before the increase in albuminuria, as has been documented in previous reports [18] [19] [20] .
To delineate the importance of this change in PTs before a change in glomeruli, we examined the effects of Sirt1 overexpression in PTspecific Flag-tagged SIRT1 TG mice. First we confirmed that TG mice overexpressed SIRT1 in PTs, but not glomeruli, using an antibody to Flag (Supplementary Fig. 1c) . Immunoblotting, immunostaining and laser microdissection followed by RT-PCR all showed that the reduction in Sirt1 expression in wild-type (WT) mice at 24 weeks after STZ treatment was prevented in the TG mice, both in the PTs and glomeruli ( Fig. 1c and Supplementary Fig. 1a,b) . Plasma glucose concentrations increased in both WT and TG diabetic mice at 4 weeks after treatment with STZ, and the increase was sustained until 24 weeks. We euthanized mice 24 weeks after STZ treatment (Supplementary Fig. 1d ). Plasma glucose concentrations did not differ between WT and TG mice at either 8 or 24 weeks after treatment (Supplementary Fig. 1d ). Body weights, blood urea nitrogen and creatinine concentrations, creatinine clearance and kidney weights also did not differ between WT and TG mice ( Supplementary Fig. 1e-i) . Eight weeks after STZ treatment, urinary albumin excretion was unchanged among the four experimental groups of mice (Fig. 1d) , although at 24 weeks after treatment, urinary albumin excretion in WT mice treated with STZ was greater than that in WT mice treated with saline (Fig. 1d) . Urinary albumin excretion in STZ-treated TG mice was lower than that in STZ-treated WT mice (Fig. 1d) . Mesangial matrix accumulations were not different between WT and TG mice treated with STZ ( Supplementary Fig. 1j ). As determined by electron microscopy (EM), the density of tight pores was not affected by STZ at 8 weeks after treatment among the four experimental groups of mice (Fig. 1e) , although WT mice treated with STZ showed higher tight pore densities than WT mice treated with saline at 24 weeks. TG mice treated with STZ showed lower tight-pore densities than WT mice treated with STZ at 24 weeks (Fig. 1e) .
Sirt1-dependent upregulation of Claudin-1 expression
To elucidate the molecular mechanisms underlying the amelioration of albuminuria by overexpression of SIRT1 in PTs, we performed DNA microarray analysis using microdissected glomerular regions to examine differences in gene expression between STZ-treated WT and TG mice. Using a Welch t test with a cutoff of P < 0.05, 26 genes showed a statistically significant upregulation of greater than fourfold in TG mice (Supplementary Table 1) , and 29 genes showed downregulation in TG mice to ≤25% of the level in WT mice (Supplementary Table 2 ). We selected four upregulated genes and four downregulated genes with known functions and confirmed the differential expression of these genes by quantitative real-time RT-PCR using whole kidney samples (Supplementary Fig. 2 ). Only Cldn1 (encoding Claudin-1) showed a marked reduction in mRNA level in TG mice treated with STZ compared to WT mice treated with STZ. In addition, among these eight genes, Cldn1 has been reported to be the most related to the pathogenesis of albuminuria 21, 22 . Therefore, we focused on changes in Claudin-1 expression.
Expression of Cldn1 mRNA, a putative parietal epithelial cell (PEC)-specific marker [23] [24] [25] , was higher in WT mice treated with STZ than npg in saline-treated WT mice. We did not see this difference in TG mice (Fig. 1f) . As determined by microarray analysis, no other isoforms of Claudin were upregulated or downregulated. Claudin-1 appeared to be expressed only in PECs of saline-treated WT mice, as determined by immunostaining (Fig. 1g) . Claudin-1 levels were higher in STZ-treated WT mice than in saline-treated WT mice, and Claudin-1 extended ectopically in podocytes in STZ-treated WT mice (Fig. 1g) .
We did not see this difference in Claudin-1 levels in either PECs or podocytes in TG mice (Fig. 1g) . Laser microdissection followed by real-time PCR revealed lower levels of Sirt1 mRNA expression in PECs and PT cells of STZ-treated as compared to saline-treated WT mice (Fig. 1h) . Cldn1 mRNA expression was substantially higher in PECs of STZ-treated as compared to saline-treated WT mice, although we detected little Cldn1 expression in PT cells of either group (Fig. 1h) .
In TG mice, Sirt1/SIRT1 mRNA expression levels were unaffected by STZ in either PTs or PECs (Fig. 1i) . We detected little expression of Cldn1 in PTs and PECs of TG mice, and its expression in these regions was unaffected by STZ (Fig. 1i) . Using immunogold EM of the foot processes of podocytes, we observed no gold particles for Claudin-1 in saline-treated WT mice, whereas we observed large numbers in STZ-treated WT mice. We did not see this difference in TG mice (Supplementary Fig. 3a-c) . Collectively these findings suggest that Sirt1 overexpression in PTs alters Claudin-1 expression in PECs and podocytes but not PT cells.
Effects of Claudin-1 expression in podocytes
To examine the effects of Claudin-1 on albuminuria, we transferred a construct containing the Cdn1 gene inserted downstream of a podocyte-specific promoter, a 2.5-kb fragment of the NPHS2 (podocin) promoter, into WT mice with the aid of a hemagglutinating virus of the Japan envelope vector 26 . Injection of the Cldn1 gene driven by a NPHS2 promoter successfully upregulated Claudin-1 expression in podocytes (Fig. 2a) . This gene transfer induced albuminuria in WT mice and aggravated albuminuria in STZ-treated mice (Fig. 2b) . These effects were accompanied by greater podocyte effacement (Fig. 2c) .
The β-catenin-Snail pathway has a role in the pathogenesis of albuminuria 27 , and Claudin-1 reportedly activates the β-cateninSnail pathway in colon epithelial cells 28 . Thus we examined whether Claudin-1 activates the β-catenin-Snail pathway in podocytes. Transfer of the Cldn1 gene upregulated both Ctnnb1 (β-catenin) and Snai1 (Snail) mRNA levels concomitantly with downregulation of the mRNAs for the slit membrane protein podocin (Nphs2) and (Fig. 2d) . Overexpression of Claudin-1 was also associated with increased expression of β-catenin and Snail and downregulated synaptopodin expression in cultured podocytes (Fig. 2e) . Collectively these findings suggest that expression of Claudin-1 in podocytes induces podocyte effacement and leads to albuminuria, presumably through the activation of β-catenin-Snail signaling.
Deficiency of Sirt1 in PTs causes albuminuria
To confirm the role of PT Sirt1 in albuminuria in diabetes, we created mice deficient in Sirt1 specifically in PTs (conditional knockout (CKO) mice) by crossing Sirt1 flox/flox mice on a C57BL/6J background with γ-glutamyl transpeptidase(γ-GT)-Cre mice. CKO mice showed specific loss of Sirt1 expression in the kidney (Fig. 2f) . Immunofluorescence staining revealed that control littermates aged 8 weeks expressed Sirt1 in the glomeruli and tubules in kidney tissues. In CKO mice, we observed almost complete elimination of Sirt1 expression in the tubules, whereas glomerular expression was unaffected, denoting tubular-specific knockout of Sirt1 (Supplementary Fig. 4a) .
We then compared phenotypes in 32-week-old mice (24 weeks after saline or STZ treatment). Microdissection followed by real-time PCR revealed lower PT Sirt1 expression levels in CKO mice than in control mice (Fig. 2g) . In addition, Sirt1 expression levels were also lower in glomeruli of CKO mice (Fig. 2g) . Sirt1 expression levels in PTs and glomeruli were lower in control mice treated with STZ and CKO mice treated with saline than in control mice treated with saline. Sirt1 expression in CKO mice treated with STZ was lower than that in CKO mice treated with saline and that in STZ-treated control mice (Fig. 2g) . The results of immunofluorescence staining (Supplementary Fig. 4a ) were consistent with those of real-time PCR. As determined by EM, the density of tight pores was higher in STZ-treated control mice and saline-treated CKO mice than in saline-treated control mice, and we observed an even higher tight pore density in STZ-treated CKO mice (Fig. 2h) . Immunostaining (Fig. 2i) , real-time PCR after laser microdissection (Fig. 2i) and immunogold EM (Supplementary Fig. 4b ) revealed higher levels of Claudin-1 expression in STZ-treated control mice and saline-treated CKO mice compared with saline-treated control mice, an effect that was further enhanced in STZ-treated CKO mice. Urinary albumin excretion was greater in STZ-treated control mice and saline-treated CKO mice than in saline-treated control mice and was even greater in STZ-treated CKO mice (Fig. 2j) . These data from PT-specific Sirt1-deficient mice confirm the pivotal role of endogenous PT Sirt1 in maintaining glomerular structure and function during the initiation of albuminuria in diabetes, as well as in normal conditions.
SIRT1 overexpression in obese and nephrectomized mice
We further investigated the effects of SIRT1 overexpression in PTs in another diabetic model and 5/6 nephrectomized (5/6Nx) mice. We crossed our SIRT1 TG mice with obese db/db mice and produced SIRT1 TG db/db mice. Plasma glucose concentrations and body weights were substantially higher in WT db/db mice and TG db/db mice as compared to nondiabetic (ND) mice. Plasma glucose concentrations were elevated by 8 weeks of age in both WT db/db and TG db/db mice, and this elevation was sustained until 32 weeks of age (Supplementary Fig. 4c ). Body weights, blood urea nitrogen and creatinine concentrations, creatinine clearance and kidney-to-body weight ratios did not differ between the WT db/db and TG db/db groups ( Supplementary Fig. 4d-h ). SIRT1 expression in WT db/db mice was lower than in WT ND mice, but there was no significant difference in SIRT1 expression levels between TG ND mice and TG db/db mice (Fig. 3a) . Urinary albumin excretion, Claudin-1 levels and the density of tight pores did not differ between 32-week-old TG ND mice and WT ND mice. However, these parameters were greater in WT db/db mice than in either type of ND mice at 32 weeks of age, when glomerular lesions were evident. In TG db/db mice, we npg observed no such difference (Fig. 3b-d) . Periodic acid-Schiff (PAS) staining revealed an increase in mesangial matrix accumulation in the diabetic groups, but there was no difference in accumulation between WT db/db and TG db/db mice (Supplementary Fig. 4i) .
To explore the role of renal tubular Sirt1 in non-diabetes related albuminuria, we performed similar experiments using 5/6Nx mice 29 . Twenty-four weeks after nephrectomy, the expression of Sirt1 was unchanged in these mice, and PT-specific SIRT1 TG mice expressed high levels of SIRT1 in the kidney (Fig. 3e) . The 5/6Nx mice exhibited albuminuria at a level that was similar to that in STZ-treated WT mice. However, PT-specific SIRT1 overexpression could not prevent albuminuria in 5/6Nx mice (Fig. 3f) . Collectively, these data indicate that the effect of PT Sirt1 in preventing albuminuria is a diabetesspecific event.
Epigenetic mechanism of SIRT1-induced Claudin-1 upregulation We further explored the mechanism regulating Claudin-1 expression using human-derived renal epithelial (HRE) cells, as this cell line expresses Claudin-1 and has a similar phenotype to that of PECs. SIRT1 expression decreased and Claudin-1 expression increased as glucose concentration increased (Fig. 4a) . Transfection of cells with increasing amounts of SIRT1 expression vectors resulted in downregulation of Claudin-1 expression (Fig. 4b) . SIRT1 overexpression blunted the upregulation of Claudin-1 by glucose (Fig. 4b) . We then investigated CpG methylation in the kidneys of TG mice treated with or without STZ. Left, methylation-specific PCR and real-time methylation-specific PCR using microdissected PECs. Right, Cldn1 mRNA expression in PECs. *P < 0.05 (ANOVA). n = 5 independent experiments. All data are shown as the mean ± s.e.m. npg the epigenetic mechanisms for regulating Claudin-1 expression 30 . A computer search indicated that CpG islands, a target for methylation, reside within the CLDN1 genes of both mice and humans (Fig. 4c) . Methylation analysis revealed that the amount of methylated CpG decreased with increasing glucose concentration in concert with upregulation of Claudin-1 (Fig. 4d) . The transfection of cells with increased concentrations of SIRT1 expression vectors induced hypermethylation of the Cldn1 gene in concert with downregulation of Claudin-1 (Fig. 4d) . Transfection of cells with an siRNA for SIRT1 induced hypomethylation of the Cldn1 gene and upregulated Claudin-1 expression (Fig. 4e) . SIRT1 overexpression blunted the hypomethylation of the Cldn1 gene CpG islands that was induced by glucose (Fig. 4f) .
Treatment of cells with 5-aza-dC, a DNA methyltransferase (Dnmt) inhibitor, reduced the level of methylation of the Cldn1 gene and increased Claudin-1 protein levels (Fig. 4g) . The methylation of the Cldn1 CpG region that was induced by overexpression of SIRT1 was suppressed by cotransfection of cells with an siRNA for Dnmt1 (Fig. 4h) but not by cotransfection of cells with siRNAs for Dnmt3a and Dnmt3b (Supplementary Fig. 5a,b) . In an inactivation model of gene expression, histone deacetylation induces histone methylation, which leads to the recruitment of Dnmt 31, 32 . We examined chromatin modification status by chromatin immunoprecipitation (ChIP) assays to confirm the molecular events in the CpG islands within the Cldn1 gene 33, 34 . Acetylation of histones H3 and H4 was greater in both CpG and nonCpG regions in cells treated with sirtinol, a Sirt1 inhibitor, than in untreated cells (Fig. 4i) . Histone H3 Lys9 dimethylation (H3K9me2) in the CpG region was decreased by sirtinol, although H4K20me2 was unaffected by sirtinol treatment (Fig. 4i) . These results suggest npg that SIRT1 deacetylated the H3 and H4 histones in both CpG and non-CpG regions and enhanced H3K9me2 in CpG regions (Fig. 4i) . They also indicate that Claudin-1 expression is regulated epigenetically through deacetylation of histones H3 and H4 by SIRT1, with subsequent CpG methylation of the Cldn1 gene by recruited Dnmt1.
We confirmed these epigenetic changes in PECs microdissected from STZ-treated SIRT1 TG mice. Diabetes-induced hypomethylation of Cldn1 CpG regions and SIRT1 overexpression led to higher levels of methylation of these regions (Fig. 4j) . In parallel with these epigenetic changes, the levels of Cldn1 mRNA expression were higher in STZ-treated WT mice than in STZ-treated TG mice (Fig. 4j) . We obtained more quantitative results by bisulfite sequencing using microdissected PECs (Supplementary Fig. 5c,d) .
Interaction between PT cells and podocytes through NMN Our data indicated that the phenotype changes in PT cells affected contiguous cells, including podocytes. We examined this interaction between PT cells and podocytes in conditioned medium (CM) experiments. We transfected a human renal PT cell line, HK-2, cultured in either normal-glucose (NG) or high-glucose (HG) conditions, with SIRT1 expression vectors (Fig. 5a) . We obtained CM from these cells and treated podocytes with or without these conditioned media. Podocytes cultured without CM expressed Sirt1 protein but had undetectable levels of Claudin-1 protein. In the absence of CM, HG culture conditions did not change the levels of these molecules. However, CM from HK-2 cells cultured in NG conditions induced higher levels of Sirt1 expression in podocytes. Exposure of podocytes to CM from HK-2 cells cultured in HG conditions downregulated Sirt1 and upregulated Claudin-1 in podocytes. These effects were diminished in podocytes exposed to CM from HK-2 cells transfected with the SIRT1 expression vector and cultured in HG conditions (Fig. 5b) . Thus, the CM from HK-2 cells contained some factor that was responsible for the alteration of Sirt1 expression in podocytes.
Nicotinic acid metabolites are candidates for this effect because they are related to Sirt1 expression 35 and activity 36, 37 . In this metabolic pathway, nicotinamide (NAM) is converted into NMN by intracellular-type NAM phosphoribosyltransferase. NMN is further converted into NAD + by nicotinamide mononucleotide adenylyl transferase. NAD + is then converted into NAM by Sirt1, forming a metabolic loop 36, 38 . In our culture system, NMN concentrations and the NAD + -to-NADH ratio were lower in CM from HK-2 cells cultured in the HG condition than in CM from HK-2 cells cultured in the NG condition. We did not observe such a difference in CM from SIRT1-transfected HK-2 cells (Fig. 5c) . Exogenous supplementation of NMN into CM from HK-2 cells cultured in the HG condition induced higher levels of Sirt1 and lower levels of Claudin-1 in podocytes. Sirtinol abrogated these effects of NMN treatment (Fig. 5d) . We did not observe these molecular changes when we used mannitol in the place of glucose, indicating that osmotic changes had no effects (Supplementary Fig. 6a-f and Supplementary Results). Collectively these findings suggest that Sirt1 prevented the HG-induced decrease in NMN and NAD + concentrations in CM, which could have contributed, at least in part, to the changes in Sirt1 expression and probably the subsequent alteration of Claudin-1 expression in podocytes.
We then measured NMN concentrations inside the cells in CM experiments. We detected NMN photoactivated by pretreatment with perchloric acid and acetophenone at high temperature 39 in HK-2 cells (Fig. 5e) . HK-2 cells cultured in HG contained lower concentrations of NMN than those cultured in NG (Fig. 5e) . This difference was reversed in HK-2 cells transfected with the SIRT1 expression vector. In podocytes, basal concentrations of NMN were almost undetectable (Fig. 5e) . One and two hours after exposure to NG CM, NMN concentrations npg inside podocytes were higher. The NMN concentration was low when we treated podocytes with HG CM but was higher in podocytes treated with CM from SIRT1-transfected HK-2 cells (Fig. 5e) . These data indicate that NMN synthesized and secreted by HK-2 cells was taken up by podocytes. Next, we directly measured tissue NMN concentrations in kidneys using this method. We detected NMN mainly in tubular regions (Fig. 5f) , probably because of the high expression levels of the NMN-producing enzyme iNampt (Fig. 5g) . NMN levels were lower in WT mice treated with STZ than in WT mice treated with saline, and this difference was less apparent in SIRT1 TG mice (Fig. 5f) . We consistently saw weaker immunostaining for iNampt in STZ-treated compared with saline-treated WT mice, whereas we saw stronger immunostaining in STZ-treated compared with saline-treated TG mice (Fig. 5g) . Similarly, NMN concentrations were lower in STZ-treated control mice and saline-treated CKO mice than in saline-treated control mice and were even lower in STZtreated CKO mice (Supplementary Fig. 6g ). Immunostaining for iNampt was weaker in STZ-treated control mice and saline-treated CKO mice than in saline-treated control mice and was even weaker in STZ-treated CKO mice (Supplementary Fig. 6h ). These results suggest that iNampt levels are affected, at least in part, by glucose or the Sirt1-determined tissue NMN concentrations around PTs, which regulate Sirt1 and Claudin-1 expression levels in podocytes.
To confirm a role for NMN in the progression of diabetes-induced albuminuria, we examined the effects of FK866, an inhibitor of iNampt. FK866 at the dose of 30 mg per kg body weight in 8-week-old male WT C57BL/6J mice decreased NMN concentrations (Supplementary Fig. 7a ), leading to higher levels of Claudin-1 expression (Supplementary Fig. 7b ) and albuminuria ( Supplementary  Fig. 7c ). EM revealed that FK866 induced higher tight-slit pore density and Claudin-1 levels in podocytes (Supplementary Fig. 7d,e) .
Our data imply a pivotal role for the molecular interplay between iNampt and NMN in PTs and Sirt1 and Claudin-1 in podocytes in diabetes-induced albuminuria. We thus investigated retrograde interplay from tubular cells to podocytes in an in vivo system. N-methylanthraniloyl (Mant)-NMN is an autoimaging substance that cannot be synthesized endogenously 40, 41 . One hour after injection into the renal artery in 8-week-old control mice, Mant-NMN accumulated in tubules, and 2 h after injection, its accumulation could be detected in glomeruli (Fig. 5h) . These temporal changes in the localization of Mant-NMN strongly suggested that NMN was taken up by tubular cells and thereafter delivered into glomeruli. In CKO mice that lack the ability to supply NMN to glomeruli from proximal tubules, the late peak in podocytes was almost abolished (Fig. 5i) . This result supports the hypothesis that the NMN accumulation in podocytes is derived from proximal tubules and not from slow accumulation in glomeruli. However, we need to further investigate the detailed mechanisms underlying NMN secretion or absorption. Presumably, NMN absorption in podocytes will depend on nucleotide receptors such as P2X or P2Y 42 .
SIRT1 and Claudin-1 expression in human renal biopsy samples We evaluated renal the expression of SIRT1 and Claudin-1 in human specimens from 11 subjects with diabetes (Supplementary Table 3) . SIRT1 expression in both PTs and glomerular regions was lower, and Claudin-1 expression in the glomerular region was higher, in the kidneys of subjects with heavy proteinuria (12 g d −1 ) compared with those with moderate proteinuria (1.5 g d −1 ) (Fig. 6a) . Claudin-1 expression was negatively correlated with SIRT1 expression in both PTs and glomerular regions (Fig. 6b) .
Among several clinical parameters, only proteinuria was correlated with both PT and glomerular SIRT1 immunostaining, as well as with glomerular Claudin-1 immunostaining (Fig. 6c) . There were no correlations between estimated glomerular filtration rate (eGFR) and immunostaining patterns for either protein (Fig. 6d) .
DISCUSSION
Our data reveal that reduced Sirt1 expression in PTs leads to reduced Sirt1 levels and higher Claudin-1 levels in glomeruli, leading to the initiation of albuminuria in a diabetic mouse model. These findings indicate a protective role for PT Sirt1 against albuminuria that is specific for diabetes-induced albuminuria.
We also show direct epigenetic regulation of Cldn1 gene expression by SIRT1. The important role of Dnmt1 in SIRT1-induced gene methylation in the present study is consistent with a recent study showing that Sirt1 directly deacetylates and activates Dnmt1 (ref. 43) . The results in our PT-specific genetically engineered mice imply that the molecular changes in PTs induced the phenotype changes in glomeruli and podocytes.
We also show a role for NMN as a candidate mediator of the interplay between PT cells and podocytes. We confirmed this retrograde interplay by tracing photoactivated labeled NMN both in vitro and in vivo. Our data suggest that NMN derived from PT cells is absorbed by podocytes; however, more work will be needed to confirm this hypothesis (Supplementary Fig. 8) .
We also show that expression of SIRT1 and Claudin-1 is correlated with levels of proteinuria in human renal biopsy samples from subjects with diabetes. Because neither of our diabetic mouse models developed severe diabetic nephropathy, we should interpret the present data carefully. In addition, the mechanisms regulating NMN concentrations in PTs on the basis of glucose condition or Sirt1 expression level remain unclear. However, because the clinical data are consistent with the results obtained from mouse models, we suggest that an initial downregulation of Sirt1 expression in PTs, which is followed by downregulation of Sirt1 and upregulation of Claudin-1 in glomeruli, has a role in the initial changes in diabetes-induced albuminuria 44 . The results of this study could contribute to new therapeutic strategies to prevent diabetes-induced albuminuria.
NMN, an intermediate of nicotinic acid metabolism, is synthesized by iNAMPT. In the diabetic milieu, reduced expression of Sirt1 causes downregulation of iNAMPT, presumably by direct transcriptional mechanisms 45 . This decrease in iNAMPT leads to the reduction in the levels of NMN secreted from tubular cells. Although it would be diluted by urine during retrograde flow, in the microenvironment near podocytes inside the Bowman's capsule, the continuous secretion of NMN by proximal tubular cells or PECs would maintain a certain level of NMN around podocytes. This level might decrease in the diabetic milieu, although the direct measurement of local NMN concentrations remains to be investigated. Further, a decrease in NMN taken up in podocytes downregulates Sirt1, which epigenetically increases Claudin-1. Claudin-1 is reported to activate the β-catenin-Snail pathway 28 , and as demonstrated in the present study, this activation would change glomerular barrier function through downregulating synaptopodin or podocin expression in podocytes 27 . The detailed mechanisms of these molecular interplays in podocytes warrant further investigations.
METHODS
Methods and any associated references are available in the online version of the paper. 
